Trials / Unknown
UnknownNCT05055414
Arformoterol/Budesonide for COVID-19
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2 Study to Evaluate the Efficacy and Safety of UI030 in COVID-19 Patients
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Korea United Pharm. Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double-blind, placebo-controlled, parallel, phase 2 study to evaluate the efficacy and safety of UI030 in COVID-19 patients
Detailed description
Patients with moderate and severe COVID-19 were randomly assigned (1:1) to receive either UI030 (Budesonide/Arformoterol dry powder inhaler, 2 inhalations b.i.d) or placebo for 2 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UI030 | Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2022-10-01
- Completion
- 2022-11-01
- First posted
- 2021-09-24
- Last updated
- 2021-09-24
Source: ClinicalTrials.gov record NCT05055414. Inclusion in this directory is not an endorsement.